N-terminal phosphorylation of the dopamine transporter is required for amphetamine-induced efflux.
Amphetamine (AMPH) elicits its behavioral effects by acting on the dopamine (DA) transporter (DAT) to induce DA efflux into the synaptic cleft. We previously demonstrated that a human DAT construct in which the first 22 amino acids were truncated was not phosphorylated by activation of protein kinase C, in contrast to wild-type (WT) DAT, which was phosphorylated. Nonetheless, in all functions tested to date, which include uptake, inhibitor binding, oligomerization, and redistribution away from the cell surface in response to protein kinase C activation, the truncated DAT was indistinguishable from the full-length WT DAT. Here, however, we show that in HEK-293 cells stably expressing an N-terminal-truncated DAT (del-22 DAT), AMPH-induced DA efflux is reduced by approximately 80%, whether measured by superfusion of a population of cells or by amperometry combined with the patch-clamp technique in the whole cell configuration. We further demonstrate in a full-length DAT construct that simultaneous mutation of the five N-terminal serine residues to alanine (S/A) produces the same phenotype as del-22-normal uptake but dramatically impaired efflux. In contrast, simultaneous mutation of these same five serines to aspartate (S/D) to simulate phosphorylation results in normal AMPH-induced DA efflux and uptake. In the S/A background, the single mutation to Asp of residue 7 or residue 12 restored a significant fraction of WT efflux, whereas mutation to Asp of residues 2, 4, or 13 was without significant effect on efflux. We propose that phosphorylation of one or more serines in the N-terminus of human DAT, most likely Ser7 or Ser12, is essential for AMPH-induced DAT-mediated DA efflux. Quite surprisingly, N-terminal phosphorylation shifts DAT from a "reluctant" state to a "willing" state for AMPH-induced DA efflux, without affecting inward transport. These data raise the therapeutic possibility of interfering selectively with AMPH-induced DA efflux without altering physiological DA uptake.
Khoshbouei
Habibeh
H
Department of Molecular Physiology and Biophysics and Center for Molecular Neuroscience, Vanderbilt University, Nashville, Tennessee, USA.
Sen
Namita
N
Guptaroy
Bipasha
B
Johnson
L 'Aurelle
L'
Lund
David
D
Gnegy
Margaret E
ME
Galli
Aurelio
A
Javitch
Jonathan A
JA
D000662:Amphetamines / Q000737:chemistry*; D001224:Aspartic Acid / Q000737:chemistry; D019921:Biotinylation; D002460:Cell Line; D002462:Cell Membrane / Q000378:metabolism; D002478:Cells, Cultured; D050483:Dopamine Plasma Membrane Transport Proteins / Q000378:metabolism / Q000502:physiology*; D004594:Electrophysiology; D006801:Humans; D015151:Immunoblotting; D007700:Kinetics; D008969:Molecular Sequence Data; D009154:Mutation; D010477:Perfusion; D010641:Phenotype; D010766:Phosphorylation; D010957:Plasmids / Q000378:metabolism; D011493:Protein Kinase C / Q000378:metabolism; D017434:Protein Structure, Tertiary; D012694:Serine / Q000737:chemistry; D014162:Transfection; D014439:Tyramine / Q000737:chemistry
D000662:Amphetamines; D050483:Dopamine Plasma Membrane Transport Proteins; D001224:Aspartic Acid; D012694:Serine; D011493:Protein Kinase C; D014439:Tyramine